UBS analyst Kevin Caliendo raised the firm’s price target on Premier (PINC) to $28.25 from $26 and keeps a Neutral rating on the shares after the company entered into an agreement to be acquired by an affiliate of Patient Square Capital for $28.25 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PINC:
- Hold Rating Maintained Amid Premier’s Acquisition by Patient Square Capital
- Premier price target raised to $28.25 from $25 at Canaccord
- Pfizer to acquire Metsera, Oracle names new CEOs: Morning Buzz
- Premier Announces Merger with Patient Square Capital
- Premier to be acquired by Patient Square Capital for $28.25 per share in cash